Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 252

Similar articles for PubMed (Select 23820571)

1.

Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure.

Lok DJ, Klip IT, Lok SI, Bruggink-André de la Porte PW, Badings E, van Wijngaarden J, Voors AA, de Boer RA, van Veldhuisen DJ, van der Meer P.

Am J Cardiol. 2013 Sep 15;112(6):831-7. doi: 10.1016/j.amjcard.2013.05.013. Epub 2013 Jun 29.

PMID:
23820571
2.

Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.

Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL.

Eur Heart J. 2009 May;30(9):1057-65. doi: 10.1093/eurheartj/ehn600. Epub 2009 Jan 23.

3.

Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.

de Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A.

Am Heart J. 2012 May;163(5):821-8. doi: 10.1016/j.ahj.2012.03.004.

PMID:
22607860
4.

Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study.

Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E.

Circulation. 2011 May 17;123(19):2101-10. doi: 10.1161/CIRCULATIONAHA.110.979740. Epub 2011 May 2.

5.

Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.

Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, Zamora E, Urrutia A, Lupón J.

J Am Coll Cardiol. 2014 Jan 21;63(2):158-66. doi: 10.1016/j.jacc.2013.07.087. Epub 2013 Sep 24.

6.

Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.

Lupón J, de Antonio M, Galán A, Vila J, Zamora E, Urrutia A, Bayes-Genis A.

Mayo Clin Proc. 2013 Mar;88(3):234-43. doi: 10.1016/j.mayocp.2012.09.016. Epub 2013 Feb 4. Erratum in: Mayo Clin Proc. 2013 May;88(5):532.

PMID:
23384388
7.

Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry).

Park JJ, Choi DJ, Yoon CH, Oh IY, Jeon ES, Kim JJ, Cho MC, Chae SC, Ryu KH, Yoo BS, Kang SM, Oh BH; KorHF Registry.

Am J Cardiol. 2014 Feb 1;113(3):511-7. doi: 10.1016/j.amjcard.2013.10.022. Epub 2013 Nov 9.

PMID:
24315115
8.

Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.

Goei D, Hoeks SE, Boersma E, Winkel TA, Dunkelgrun M, Flu WJ, Schouten O, Bax JJ, Poldermans D.

Coron Artery Dis. 2009 May;20(3):219-24. doi: 10.1097/MCA.0b013e3283219e47.

PMID:
19322079
9.

Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina.

Ndrepepa G, Braun S, Schulz S, Fusaro M, Keta D, Pache J, Seyfarth M, Mehilli J, Schömig A, Kastrati A.

Eur J Clin Invest. 2011 Oct;41(10):1054-62. doi: 10.1111/j.1365-2362.2011.02500.x. Epub 2011 Mar 17.

PMID:
21413976
10.

Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.

Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, Mahaffey KW, Steg PG, Storey RF, James SK; PLATO study group.

Circulation. 2014 Jan 21;129(3):293-303. doi: 10.1161/CIRCULATIONAHA.113.004420. Epub 2013 Oct 29.

11.

Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial.

Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJ, Aukrust P, Gullestad L, Kjekshus J; CORONA Study Group.

Circ Heart Fail. 2014 Jan;7(1):96-103. doi: 10.1161/CIRCHEARTFAILURE.113.000450. Epub 2013 Nov 27.

12.

Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements.

Alehagen U, Dahlström U, Rehfeld JF, Goetze JP.

Clin Chem. 2010 Nov;56(11):1718-24. doi: 10.1373/clinchem.2009.141341. Epub 2010 Sep 15.

13.

Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.

Santhanakrishnan R, Chong JP, Ng TP, Ling LH, Sim D, Leong KT, Yeo PS, Ong HY, Jaufeerally F, Wong R, Chai P, Low AF, Richards AM, Lam CS.

Eur J Heart Fail. 2012 Dec;14(12):1338-47. doi: 10.1093/eurjhf/hfs130. Epub 2012 Aug 5.

PMID:
22869458
14.

Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.

Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, Pastor-Perez F, Valdés M, Januzzi JL.

Eur J Heart Fail. 2011 Jul;13(7):718-25. doi: 10.1093/eurjhf/hfr047. Epub 2011 May 6.

PMID:
21551163
15.

High-sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N-terminal pro-b-type natriuretic peptide.

Jungbauer CG, Riedlinger J, Buchner S, Birner C, Resch M, Lubnow M, Debl K, Buesing M, Huedig H, Riegger G, Luchner A.

Clin Chem Lab Med. 2011 Nov;49(11):1899-906. doi: 10.1515/CCLM.2011.251. Epub 2011 Sep 6.

PMID:
21892905
16.

Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality.

Oluleye OW, Folsom AR, Nambi V, Lutsey PL, Ballantyne CM; ARIC Study Investigators.

Ann Epidemiol. 2013 Feb;23(2):66-73. doi: 10.1016/j.annepidem.2012.11.004. Epub 2012 Dec 8.

17.

Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism.

Lankeit M, Kempf T, Dellas C, Cuny M, Tapken H, Peter T, Olschewski M, Konstantinides S, Wollert KC.

Am J Respir Crit Care Med. 2008 May 1;177(9):1018-25. doi: 10.1164/rccm.200712-1786OC. Epub 2008 Feb 8.

PMID:
18263797
18.

Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure.

Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC.

J Am Coll Cardiol. 2007 Sep 11;50(11):1054-60. Epub 2007 Aug 24.

19.

A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure.

Richter B, Koller L, Hohensinner PJ, Zorn G, Brekalo M, Berger R, Mörtl D, Maurer G, Pacher R, Huber K, Wojta J, Hülsmann M, Niessner A.

Int J Cardiol. 2013 Sep 30;168(2):1251-7. doi: 10.1016/j.ijcard.2012.11.052. Epub 2012 Dec 4.

PMID:
23218577
20.

N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease.

Ndrepepa G, Kastrati A, Braun S, Mehilli J, Niemöller K, von Beckerath N, von Beckerath O, Vogt W, Schömig A.

Am J Med. 2006 Apr;119(4):355.e1-8.

PMID:
16564781
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk